维奈克拉在急性髓系白血病中的敏感性及耐药机制的生物信息学分析
研究从Beat AML数据库获取52例接受维奈克拉药敏试验的AML患者数据进行相关性分析,发现FLT3突变患者及外周血肿瘤负荷较高患者对维奈克拉更敏感,维奈克拉抑制FLT3相关信号通路,FOXM1和STAT3转录活性升高与耐药相关且高表达者生存期更短。
要点
- 携带FLT3突变的AML患者相比无FLT3突变者对维奈克拉表现出更高敏感性。
- 外周血肿瘤负荷较高的患者对维奈克拉更敏感。
- FOXM1和STAT3转录活性升高与维奈克拉耐药相关,高表达者生存期更短。
核心结论
- 维奈克拉可以抑制FLT3相关信号通路激活,STAT3和FOXM1转录因子的激活可能是维奈克拉耐药的关键机制之一。
研究设计与样本
- 从Beat AML数据库下载接受维奈克拉药敏试验的AML患者基因组、转录组及临床信息数据,过滤后纳入52例患者样本进行分析。
- 采用差异分析筛选与维奈克拉敏感性相关的差异基因,并使用GEO数据库转录组结果及体外实验(含Western blot)进行验证。
- 应用KEGG、GSEA及KnockTF转录因子富集分析和公共数据库探讨影响药物敏感性的关键基因。
主要发现
- 携带FLT3突变的患者相比无FLT3突变的患者对维奈克拉表现出更高的敏感性。
- 外周血肿瘤负荷较高的患者对维奈克拉更敏感。
- 转录组数据分析及体外实验验证维奈克拉抑制FLT3相关信号通路,包括FLT3表达下调及下游靶点AKT和STAT5磷酸化降低。
- KEGG通路和KnockTF转录因子富集分析提示维奈克拉耐药与FOXM1和STAT3转录活性升高有关。
- 高表达FOXM1、STAT3的患者生存期更短。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the anti-leukemic effects and resistance mechanisms of venetoclax in acute myeloid leukemia (AML). Genomic, transcriptomic, and clinical data from AML patients who underwent venetoclax drug sensitivity testing were downloaded from the Beat AML database. Correlation analysis was performed between these data and venetoclax sensitivity outcomes. Differentially expressed genes (DEGs) associated with venetoclax sensitivity were identified from transcriptomic data and subsequently validated using GEO database transcriptomic results and in vitro experiments (including Western blot). Functional enrichment analyses (KEGG and GSEA), transcription factor enrichment analysis (KnockTF), and data from public databases were employed to further investigate key genes and pathways influencing drug sensitivity. Results: After filtering the Beat AML cohort, data from 52 patient samples with available in vitro venetoclax sensitivity results were included for analysis. Patients with FLT3 mutations exhibited greater sensitivity to venetoclax compared to those with FLT3 wild-type. Correlation analysis between clinical information and drug sensitivity data indicated that higher peripheral blood tumor burden was associated with increased sensitivity to venetoclax. Transcriptomic analysis and in vitro experiments confirmed that venetoclax inhibits the FLT3-related signaling pathway, including downregulation of FLT3 expression and reduced phosphorylation of its downstream targets AKT and STAT5. KEGG pathway and KnockTF transcription factor enrichment analyses indicated that venetoclax resistance was associated with increased transcriptional activity of FOXM1 and STAT3. Moreover, high expression of FOXM1 and STAT3 correlated with shorter overall survival in patients. Conclusion: Venetoclax can inhibit the activation of FLT3-related signaling pathways. The activation of STAT3 and FOXM1 transcription factors is a potential key mechanism contributing to venetoclax resistance in AML. 目的: 探究维奈克拉对急性髓系白血病(AML)的抑癌作用及耐药机制。 方法: 从Beat AML数据库下载BCL-2抑制剂维奈克拉药敏试验的AML患者基因组、转录组及临床信息数据,对其与药敏试验结果进行相关性分析。通过对转录组数据进行差异分析,筛选出与维奈克拉治疗敏感性相关的差异基因并使用GEO数据库转录组结果及体外实验进行验证。同时应用KEGG、GSEA以及KnockTF转录因子富集分析及公共数据库进一步探讨影响药物敏感性的关键基因。 结果: 过滤得到52例进行维奈克拉药敏试验的患者数据。分析结果表明,携带FLT3突变的患者相比无FLT3突变的患者对维奈克拉表现出更高的敏感性。临床信息与药敏试验结果的相关性分析结果显示,外周血肿瘤负荷较高的患者对维奈克拉更敏感。转录组数据分析及体外实验验证维奈克拉抑制FLT3相关信号通路。KEGG、KnockTF转录因子富集分析提示维奈克拉耐药与FOXM1、STAT3转录活性升高有关,高表达FOXM1、STAT3的患者生存期更短。 结论: 维奈克拉可以抑制FLT3相关信号通路激活,而STAT3和FOXM1转录因子的激活可能是维奈克拉耐药的关键机制之一。.
引用
- Yang Y, Xu CH, Wang N, et al. [Bioinformatic analysis of venetoclax sensitivity and resistance mechanisms in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40623906. doi:10.3760/cma.j.cn121090-20250114-00028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。